OBI licensed “OBI-858 Novel Botulinum Toxin Preparation” Intellectual Property Right of Global Aesthetic Medicine to OBIGEN Pharma, Inc.

1. Date of occurrence of the event: Feb 23, 2021 2. Counterparty to the contract or commitment: OBIGEN Pharma, Inc. 3. Relationship with the Company: None 4. Starting and ending dates (or rescission date) of the contract or commitment: Feb 23, 2021 5. Major content (not applicable where rescinded): (1) OBI has signed Intellectual property […]

This article is password protected.

To view the content, please enter your password in the field below